Fast Track designation is a modest positive for development timeline optionality but does not change the binary risk of Phase 1b data expected in 2027. Monitor FORTIFY enrollment updates and any future partnership interest; the stock's low liquidity and negative historical drift suggest limited near-term catalyst from this procedural milestone alone.
Price Chart
Executive Summary
Pliant Therapeutics announced FDA Fast Track designation for PLN-101095, an oral dual integrin inhibitor for ICI-refractory solid tumors. The designation provides regulatory benefits (rolling NDA, priority review eligibility) but is a procedural milestone, not a clinical data readout. With a $66M market cap, 0% analyst bullishness, and a history of negative T+20 drift on prior reports, this is a modestly positive but low-impact event for a clinical-stage biotech.
Key Facts
- FDA Fast Track designation granted for PLN-101095 in combination with pembrolizumab for ICI-refractory solid tumors
- PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins
- Currently being evaluated in Phase 1a/1b FORTIFY trial (NCT06270706) with data expected in 2027
- Fast Track benefits include frequent FDA meetings, rolling NDA submission, and priority review eligibility
- Company market cap is approximately $66M with 0% analyst bullishness (6 Hold, 4 Sell/Strong Sell)
Financial Impact
No financial figures disclosed; Fast Track is a procedural designation with no direct revenue or cost impact
Risk Factors
- Fast Track does not guarantee approval or accelerate clinical timelines; the designation is procedural
- PLN-101095 is in early-stage Phase 1a/1b with no efficacy data yet; clinical failure risk remains high
- Company has $66M market cap with 0% analyst buy ratings, indicating low institutional conviction
- Historical T+20 performance on prior PLRX reports shows average -4.86% drift, suggesting limited positive reaction to news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3346838 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 6w ago | Press Release | $1.15 $1.15 | ▼ −0.43% | ▲ +0.55% | $1.03 (−10.00%) |
May 11, 2026 20w ago | 8-K | $1.18 $1.16 | ▼ −1.69% | ▲ +0.03% | $1.03 (−12.29%) |
May 11, 2026 20w ago | Press Release | $1.18 $1.16 | ▲ +1.69% | ▼ −0.03% | $1.03 (+12.29%) |
Apr 17, 2026 23w ago | 8-K | $1.29 $1.18 | ▼ −8.53% | ▼ −12.73% | $1.03 (−19.77%) |
Apr 7, 2026 25w ago | EFFECT | $1.31 $1.19 | ▼ −9.16% | ▼ −18.94% | $1.03 (−20.99%) |
Mar 11, 2026 29w ago | 8-K | $1.41 $1.28 | ▼ −9.22% | ▼ −11.19% | $1.03 (−26.60%) |
Mar 3, 2026 30w ago | 8-K | $1.29 $1.32 | ▲ +2.33% | ▲ +6.74% | $1.03 (−19.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access